

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5021237

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	MEDIMMUNE, LLC	06/21/2018
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	MEDIMMUNE LIMITED	
<b>Street Address:</b>	MILSTEIN BUILDING	
<b>Internal Address:</b>	GRANTA PARK	
<b>City:</b>	CAMBRIDGE	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	CB21 6GH	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	15562228
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	patents@astrazeneca.com	
<b>Correspondent Name:</b>	ASTRAZENECA/MEDIMMUNE	
<b>Address Line 1:</b>	ONE MEDIMMUNE WAY	
<b>Address Line 4:</b>	GAITHERSBURG, MARYLAND 20878	
<b>ATTORNEY DOCKET NUMBER:</b>	IL33-105-US-PCT	
<b>NAME OF SUBMITTER:</b>	DENISE ADAMS	
<b>SIGNATURE:</b>	/adamsd/	
<b>DATE SIGNED:</b>	06/25/2018	
<b>Total Attachments: 3</b>		
source=IL33-105-WO-PCT_MEDI, LLC-LTD Executed Assignment#page1.tif		
source=IL33-105-WO-PCT_MEDI, LLC-LTD Executed Assignment#page2.tif		
source=IL33-105-WO-PCT_MEDI, LLC-LTD Executed Assignment#page3.tif		

**ASSIGNMENT OF PATENT RIGHTS**

THIS ASSIGNMENT is made as of the 30<sup>th</sup> March 2016 (the "Effective Date") by and between

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("Assignor"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales whose registered office is Milstein Building, Granta Park, Cambridge CB21 6GH United Kingdom ("Assignee").


WHEREAS, Assignor has agreed to assign to Assignee the Assignor's entire right, title and interest in and to the patent applications identified in the attached Schedule (the "Applications") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:


1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
  - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
  - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
  - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

  
Signed for and on behalf of  
MEDIMMUNE, LLC  
Name: Patrick Scott Alban  
Title: Authorised Signatory

Date JUNE 21, 2018

  
Signed for and on behalf of  
MEDIMMUNE LIMITED  
Name: CHRIS WINTER  
Title: Authorised Signatory

Date 25 June 2018

**THE SCHEDULE**

<b>APPLICATIONS</b>					
<b>MedImmune Case No:</b>	<b>Country</b>	<b>Filing Type</b>	<b>Application No. and/or Title of Invention</b>	<b>Filing Date</b>	
IL33-105-AU-PCT	Australia	PCT	2016239331	30 Mar 2016	
IL33-105-BR-PCT	Brazil	PCT	BR112017020955-1	30 Mar 2016	
IL33-105-CA-PCT	Canada	PCT	2982400	30 Mar 2016	
IL33-105-CL-PCT	Chile	PCT	201702433	30 Mar 2016	
IL33-105-CN-PCT	China	PCT	201680019480.3	30 Mar 2016	
IL33-105-CO-PCT	Colombia	PCT	NC2017/0010753	30 Mar 2016	
IL33-105-EP-EPT	Europe	EPT	16712353.8	30 Mar 2016	
IL33-105-ID-PCT	Indonesia	PCT	P00201707610	30 Mar 2016	
IL33-105-IL-PCT	Israel	PCT	254551	30 Mar 2016	
IL33-105-IN-PCT	India	PCT	201717036395	30 Mar 2016	
IL33-105-JP-PCT	Japan	PCT	2017-551294	30 Mar 2016	
IL33-105-KR-PCT	Korea	PCT	10-2017-7030935	30 Mar 2016	
IL33-105-MX-PCT	Mexico	PCT	MX/a/2017/012616	30 Mar 2016	
IL33-105-MY-PCT	Malaysia	PCT	PI 2017703606	30 Mar 2016	
IL33-105-NZ-PCT	New Zealand	PCT	736026	30 Mar 2016	
IL33-105-RU-PCT	Russia	PCT	2017134909	30 Mar 2016	
IL33-105-SG-PCT	Singapore	PCT	11201707593U	30 Mar 2016	
IL33-105-TW-NP	Taiwan	NP	105110432	31 Mar 2016	
IL33-105-US-PCT	United States	PCT	15/562,228	30 Mar 2016	
IL33-105-WO-PCT	WO	PCT	PCT/EP2016/056973	30 Mar 2016	
IL33-105-ZA-PCT	South Africa	PCT	2017/07355	30 Mar 2016	

**Priority Application:**

US62/140,913 filed 31 March 2015